{
    "title": "Risk Factors for Adverse Events of Nanoliposomal Irinotecan Plus 5-Fluorouracil and L-leucovorin",
    "pmid": "38707740",
    "pmcid": "PMC11062152",
    "study_parameters": [
        {
            "Study Parameters ID": 1452474677,
            "Variant Annotation ID": 1452474670,
            "Study Type": null,
            "Study Cases": 29.0,
            "Study Controls": null,
            "Characteristics": "diarrhea greater than grade 1 during Nanoliposomal irinotecan +  5-fluorouracil (5-FU) and leucovorin treatment",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.943",
            "Ratio Stat Type": null,
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": "1452474670"
        },
        {
            "Study Parameters ID": 1452474729,
            "Variant Annotation ID": 1452474678,
            "Study Type": null,
            "Study Cases": 31.0,
            "Study Controls": null,
            "Characteristics": "predictive factors for leukopenia (multiple regression) during Nanoliposomal irinotecan +  5-fluorouracil (5-FU) and leucovorin treatment",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.009",
            "Ratio Stat Type": null,
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": "1452474678"
        },
        {
            "Study Parameters ID": 1452474688,
            "Variant Annotation ID": 1452474678,
            "Study Type": null,
            "Study Cases": 31.0,
            "Study Controls": null,
            "Characteristics": "predictive factors for neutropenia (multiple regression) during Nanoliposomal irinotecan +  5-fluorouracil (5-FU) and leucovorin treatment",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.017",
            "Ratio Stat Type": null,
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": "1452474678"
        }
    ],
    "var_drug_ann": [],
    "var_pheno_ann": [
        {
            "Variant Annotation ID": 1452474670,
            "Variant/Haplotypes": "UGT1A1*1, UGT1A1*6, UGT1A1*28",
            "Gene": "UGT1A1",
            "Drug(s)": "fluorouracil, irinotecan, leucovorin",
            "PMID": 38707740,
            "Phenotype Category": "Toxicity",
            "Significance": "no",
            "Notes": "Diarrhea during nal-IRI/FL treatment was observed in seven (24.1%) of 29 patients, who had not been prescribed any antidiarrhea medication at the commencing time of nal-IRI. The rest of seven patients were excluded, since they received loperamide for diarrhea symptoms at the start of therapy. The incidence of grade â‰¥1 diarrhea in patients with UGT1A1*6 or *28 (-/-), (+/-), and (+/+) were 27.3%, 21.4%, and 25.0%, respectively (Figure 1). Multivariate analysis did not extract any risk factors, which significantly affected the development of diarrhea possibly induced by nal-IRI/FL",
            "Sentence": "UGT1A1 *6 + *28 is not associated with increased risk of Diarrhea when treated with fluorouracil, irinotecan and leucovorin in people with Pancreatic Neoplasms and Neoplasm Metastasis as compared to UGT1A1 *1/*1.",
            "Alleles": "*6 + *28",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Diarrhea",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": "and",
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Other:Pancreatic Neoplasms, Other:Metastatic neoplasm",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": "*1/*1",
            "Comparison Metabolizer types": null,
            "PMID_norm": "38707740",
            "Variant Annotation ID_norm": "1452474670"
        },
        {
            "Variant Annotation ID": 1452474678,
            "Variant/Haplotypes": "UGT1A1*1, UGT1A1*6, UGT1A1*28",
            "Gene": "UGT1A1",
            "Drug(s)": "fluorouracil, irinotecan, leucovorin",
            "PMID": 38707740,
            "Phenotype Category": "Toxicity",
            "Significance": "no",
            "Notes": "Grade 3 or 4 leukopenia and neutropenia in the UGT1A1*6 or *28 (+/+) group demonstrated an incidence rate of 50.0%, indicating a higher tendency than those in UGT1A1*6 or *28 (-/-) and (+/-) groups at 7.1% and 12.5%, respectively (p=0.085 for each) (Figure 2C and D). Multiple regression analyses revealed that the UGT1A1*6 or *28 (+/+) genotype, high AST value before the nal-IRI/FL therapy, and pancreatic head cancer were significantly associated with decreased white blood cell count (p=0.009, 0.019, and 0.030, respectively) (Table III), and that of UGT1A1*6 or *28 (+/+) was significantly related to decreased neutrophil count (p=0.017)",
            "Sentence": "UGT1A1 *6/*6 + *28/*28 + *6/*28 is associated with increased risk of Neutropenia or Leukopenia when treated with fluorouracil, irinotecan and leucovorin in people with Pancreatic Neoplasms and Neoplasm Metastasis as compared to UGT1A1 *1/*1.",
            "Alleles": "*6/*6 + *28/*28 + *6/*28",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Neutropenia, Side Effect:Leukopenia",
            "Multiple phenotypes And/or": "or",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": "and",
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Other:Pancreatic Neoplasms, Other:Metastatic neoplasm",
            "Multiple phenotypes or diseases And/or": "and",
            "Comparison Allele(s) or Genotype(s)": "*1/*1",
            "Comparison Metabolizer types": null,
            "PMID_norm": "38707740",
            "Variant Annotation ID_norm": "1452474678"
        }
    ],
    "var_fa_ann": []
}